Link found between infections and preterm birth
Bacteria or fungi in a mother's amniotic fluid may play a larger role in premature birth than previously believed, according to the August 26 PLoS One.
Bacterial or fungal infections in a mother's amniotic fluid may play a larger role in premature birth than previously believed, according to the August 26 PLoS One.
Researchers examined the amniotic fluid of 166 women who went into preterm labor, 113 of whom had preterm babies. They found that 15% of the fluid samples contained bacteria or fungi, higher than previous estimates. Of the samples with microbes, all were from mothers who had their babies prematurely.
Researchers speculated that amniotic fluid infected with bacteria or fungi may trigger an inflammatory response in the pregnant mother, thus contributing to preterm birth.
Stress ulcer prophylaxis does not provide prevention of gastrointestinal bleeding in neonates
December 4th 2023In a poster abstract presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting & Exhibition held in Anaheim, California, stress ulcer prophylaxis (SUP) did not appear to provide benefit for prevention of gastrointestinal bleeding and did not increase SUP-associated adverse effects.
CDC recommends nirsevimab be prioritized for highest-risk infants amid limited availability
October 26th 2023The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.
Preterm infant HRQOL: Long-term impacts and determinants
October 21st 2023A recent study was highlighted at the 2023 American Academy of Pediatrics National Conference & Exhibition that shed light on the long-term impact of very preterm birth on the health-related quality of life (HRQOL) of infants and identified key determinants.
Navigating a complex case of pediatric COVID-19 with immunomodulatory therapies
October 21st 2023Eculizumab and anakinra should be considered in critically ill patients with severe infections that require immunomodulating therapies for life-threatening dysregulation, according to a poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition.
